No Data
Zhijiang Biotech: 2024 Annual Report
Zhijiang Biotech: 2024 Annual Report Summary
Zhijiang Biological (688317.SH): The proportion of revenue from the US business is relatively small.
On April 16, Gelonghui reported that Zhijiang Biotech (688317.SH) stated on the interactive platform that currently, the company's Business in the U.S. accounts for a small proportion of overall revenue, and the recent tariff policy adjustment has a limited direct impact on the company's Business. The company will continue to pay attention to policy and market dynamics, further optimize its Operation strategy to enhance risk resistance capacity, and ensure steady development of its Business. The company will also strictly adhere to information disclosure requirements and timely fulfill the disclosure obligations for significant matters.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhijiang Biological (688317.SH): A total of 2.70% of the company's shares have been repurchased.
Gelonghui, April 1st丨Zhijiang Bio (688317.SH) announced that as of March 31, 2025, the company has repurchased a total of 5.1794 million shares through the centralized bidding trading method on the Shanghai Exchange, accounting for 2.70% of the company's current total share capital. The highest price for the repurchase was 17.88 yuan per share, the lowest price was 16.02 yuan per share, and the total amount paid was 89.0489 million yuan (excluding stamp duty, trading commissions, and other transaction fees).
Zhijiang Bio (688317.SH) has obtained a medical instruments registration certificate.
Zhijiang Biology (688317.SH) announced that recently one of its products obtained the national Class III medical instruments registration certificate, production...
Some Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) Shareholders Look For Exit As Shares Take 27% Pounding
